April 16, 2026 08:14 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR: Supreme Court allows voters restored by tribunal till April 21 and 27 to vote | 'Women won't spare you': PM Modi warns Opposition over resistance to quota bill | Vijay booked in 3 cases over poll code violation ahead of Tamil Nadu polls | 'Black law': Stalin burns copy of 'delimitation' bill, slams Modi govt | TCS halts Nashik BPO operations amid sexual abuse, conversion allegations | ‘We are surprised’: SC stays Pawan Khera’s bail over remarks on Himanta Biswa Sarma’s wife | Historic shift: Bihar gets first BJP CM as Samrat Choudhary takes oath | 'ECI deviated from Bihar procedure': Supreme Court raises concerns over voter deletion in Bengal SIR | Noida workers’ protest turns violent: Stones pelted, vehicles damaged over wage hike demand | Oil prices jump above $103 a barrel as US moves to block Iran-linked shipping
AstraZeneca
Pixabay

AstraZeneca's COVID-19 vaccine trial to resume in US

| @indiablooms | Oct 24, 2020, at 03:28 pm

Washington/Xinhua: Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.